Skip to main content
search

Conference: Bio-IT World Conference and Expo US 2026

Date: May 19 - 21, 2026

Location: Omni Boston Hotel at the Seaport in Boston, MA

Booth: 401

From molecule design and registration to first-in-human dose, the path from chemistry to clinic is ripe for earlier infusions of intelligence. What properties and bioactivity can we predict from structure alone? What could screening assays tell us about the clinical risks of off-target receptor interactions? And how can we use the combination of biosimulation and empirical PK/PD to select the optimal first-in-human dose and formulation?

At the same time, the profusion of modalities from small molecules to biomolecules to hybrids is pushing registration and compliance to become more exact and more flexible. How do we optimize those workflows so that they stay ahead of scientific discovery and evolving international regulations?

Meet us there

Visit our booth to discuss these and related questions. While there, you can explore Certara solutions spanning:

  • compound design, registration, compliance and more with Chemaxon
  • self-service data access and analysis of structure-activity relationships with D360
  • new capabilities in biosimulation with Certara IQ™ and Simcyp®
  • Deep learning, data fabrics, agentic-inspired workflow design with Certara.AI

Don’t miss our demos on Wednesday, May 20 and Thursday, May 21! Be sure to select your topic of interest in the form below. All demos will take place at our booth (#401).

Data access, self-service queries, and dashboards in D360
9:30 – 9:50am on Wednesday

The new Marvin chemical drawing tool from Chemaxon
2:30 – 3pm on Wednesday
9:45 – 10:10am on Thursday

Peptide design and sequence alignment in D360
1:35 – 2:00 pm on Wednesday
1:50 – 2:10pm on Thursday

Compound registration with Chemaxon
3 – 3:25pm on Wednesday
10:10 – 10:30am on Thursday

From screening assays to off-target risk assessment in D360
2:10 – 2:30pm on Thursday

Hear us speak

Wednesday, May 20, 12:25 - 12:50pm
Applying AI-Driven Mechanistic Biosimulation Decision-Making into Drug Discovery

Speaker: Leif E. Pedersen, President, Certara

Explore how PBPK/QSP, machine learning, and integrated data workflows can bring model-informed drug development into the DMTA cycle, helping teams translate in vitro and in silico signals into candidate-selection decisions, first-in-human dosing, drug-drug interaction assessment, formulation and safety.

Leif E. Pedersen

President, Chief Commercial Officer

Leif E. Pedersen is a seasoned software industry executive with more than 35 years of experience delivering software solutions across multiple industries and a proven track record of delivering high value customer-driven innovative software solutions. Mr. Pedersen was most recently senior operating partner at SymphonyAI responsible for portfolio companies across life sciences, healthcare, industrial, and defense industries.

Previously, Mr. Pedersen was chief executive officer of BIOVIA at Dassault Systèmes, a scientific software brand providing solutions for life and material sciences industries. Before joining BIOVIA, Mr. Pedersen served as executive vice president at Innovative Interfaces; senior vice president at Accelrys Software, Inc.; and vice president at Siemens Corporation. Mr. Pedersen has also held executive leadership positions with Vignette Corporation, Novell Inc., CA Technologies, and Oracle Corporation.

Let's discover a smarter way to advance therapies

Submit this form to share your interests and questions. We’ll respond with some meet-up ideas to get you in conversation with our relevant experts.